HCM - HUTCHMED Ltd Short-Term Debt to Capital

hutch-med.com - graphic logo of issuer HCM

HUTCHMED (China) Limited (HCM) specializes in developing advanced oncology treatments. The market capitalization trend, currently at 0.01, reflects the dynamics of a business generating revenue from the sale of innovative medicines and healthcare products in the PRC. The model's scalability is driven by patent law and low production costs; however, high R&D expenditures and the risk of FDA rejection remain significant challenges.

Ratio of Short-Term Indebtedness to Capital: Hutchison MediPharma (HCM) for 07/04/2022 - 11/01/2026

Analytical breakdowns for hutch-med.com (HCM)

- stock value and consensus price forecast:
Price Chart HUTCHMED Ltd|HCM - Broker Consensus Forecast
- market capitalization statistics:
Market Capitalization Hutchison MediPharma|HCM - Total Enterprise Value
- book capitalization information:
Net Assets per Single Share HUTCHMED|HCM - Accounting Value of Company|Market Capitalization to Book Value Ratio hutch-med.com|HCM - Company Total Assets
- debt level and financial liquidity data:
Debt to Equity HUTCHMED (China) Limited|HCM - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio HUTCHMED|HCM - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Hutchison MediPharma|HCM - Long-Term Debt|Company Short-Term Debt HUTCHMED|Quick Ratio hutch-med.com
- company profitability and valuation multiples indicators:
HCM - Net Income
Fundamental valuation:HCM HUTCHMED Ltd
Signature product of Hutchison MediPharma

This ratio determines the company's dependence on short-term liabilities relative to equity, allowing for an assessment of liquidity risk and the efficiency of financial leverage. By analyzing the history of short-term debt to equity, an investor can correlate the debt load with HUTCHMED (HCM) expenditures on upgrading facilities to GMP standards and the intensive operation of R&D centers.

Competitors of HUTCHMED (China) Limited (HCM)

Short-Term Debt to Equity Incyte Corp. (INCY)|Nuvation Corp - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital DAWN (Day One)|monopartx.com (MNPR) - Current Liabilities to Capital|INBX - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital IMAB (I-Mab)|FENC: Short-Term Debt to Capital|Heron Therapeutics, Inc. (HRTX) - Short-Term Debt to Capital|Short-Term Debt to Equity Nuvectis Pharma, Inc.|Short-Term Debt to Equity CHRS|Short-Term Debt to Equity Ratio CRBP (Corbus Pharmaceuticals Holdings)|CRDF (cardiffoncology.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity BeyondSpring Pharma BYSI|BioAtla Inc (BCAB) - Current Liabilities to Capital|LIXT - Short-Term Debt to Equity|CTXR (Citius Pharmaceuticals) - Short-Term Debt to Capital Ratio|CLRB: Short-Term Debt to Capital|Short-Term Debt to Equity Ratio BioLineRx Ltd|Short-Term Debt to Equity Can-Fite BioPharma, Ltd.|Current Liabilities to Capital Aprea APRE|Short-Term Debt to Equity Kazia Therapeutics (KZIA)|Short-Term Debt to Equity SLXN (silexion.com)|Short-Term Debt to Equity NuCana NCNA|Chimerix Inc. (CMRX) - Current Liabilities to Capital|Cyclacel Pharmaceuticals Inc. - Short-Term Debt to Capital|Short-Term Indebtedness to Equity G1 Therapeutics, Inc. (GTHX)|KRON (Kronos Bio, Inc.) - Short-Term Debt to Equity Ratio|Current Liabilities to Capital kintara.com (KTRA)|Short-Term Debt to Equity Ratio ONCT|PRTG: Ratio of Short-Term Indebtedness to Capital